Heartseed Advances Regenerative Cell Therapy Approaches for Severe Heart Failure

Advanced iPS cell- derived heart muscle cell therapies designed to restore lost heart muscle and
bring new possibilities to patients with severe heart failure.

LOS ANGELES , CA, UNITED STATES, September 14, 2026 /EINPresswire.com/ — Heartseed is dedicated to developing novel therapies for severe heart failure, a life-threatening condition with limited treatment options for many advanced
patients beyond heart transplantation. Through advanced cell therapy, the company aims to fundamentally restore lost heart muscle, shifting care from managing the progression of the disease to active recovery.

Severe heart failure remains one of the most urgent challenges in cardiovascular medicine. For
patients and families, the condition can mean ongoing physical limitation, repeated
hospitalization, reduced quality of life, and uncertainty about the future. While current treatments
can help manage symptoms and slow progression, Heartseed is working toward a more
restorative approach: helping the heart regain function by replacing or supplementing damaged
heart muscle.

Using high-purity heart muscle cells made from iPS cells, Heartseed forms tiny cell clusters
called cardiomyocyte spheroids. This Japan-born approach is designed to enhance cell
engraftment while minimizing the risk of tumorigenesis and arrhythmia after transplantation, a
long-standing challenge in the field.

Heartseed’s scientific approach focuses on generating highly purified ventricular cardiomyocytes
— the heart muscle cells responsible for the main pumping function of the heart — and
organizing them into spheroids that are designed to support integration with existing heart tissue.
The goal is to create a therapy that can be delivered to damaged areas of the heart and potentially
help restore lost cardiac function.

The company is now advancing two approaches: open-chest surgical transplantation and catheter-based administration. One-year clinical trial results for the surgical approach showed promising safety and efficacy outcomes, supporting plans to apply for approval in Japan within 2026. In parallel, patient enrollment is actively progressing for the catheter-based approach, aiming to bring transformative heart failure therapies closer to patients worldwide.

The open-chest surgical approach is intended to place the cardiomyocyte spheroids directly into targeted areas of damaged heart tissue. The catheter-based approach, meanwhile, is being developed with the goal of reducing the physical burden on patients and potentially expanding access to regenerative therapies in the future.

Heartseed’s work reflects a broader scientific movement in cardiovascular medicine: the possibility that damaged heart muscle may one day be restored rather than only managed. That shift could represent a profound change in how severe heart failure is approached, particularly for patients who currently face limited options.

The company’s progress also underscores Japan’s growing role in the field of regenerative medicine. By combining iPS cell science, cell purification, spheroid formation, delivery technology, and clinical development, Heartseed is working to move cardiac regenerative medicine from laboratory possibility toward therapeutic reality.

Heartseed has also been selected to appear in the Breakthroughs™ Public Service
Announcement series, in a segment focused on cardiac regenerative medicine and the global
effort to address severe heart failure. The national and international PSA is designed to help both
public and professional audiences better understand the science behind regenerative cardiology,
the human impact of heart failure, and the emerging possibility of restoring damaged heart
muscle through advanced cell therapy, and will be seen throughout the US and the world on
major news and information networks.

The Breakthroughs™ feature presents Heartseed’s work within a broader public-interest story:
the future of cardiovascular care may depend not only on managing disease, but on developing
therapies that aim to repair what disease has damaged.

About Heartseed
Heartseed is a cardiac regenerative medicine company dedicated to developing novel therapies
for severe heart failure. Using high-purity heart muscle cells derived from iPS cells, Heartseed
forms cardiomyocyte spheroids designed to support cell engraftment and integration with
existing heart tissue. The company is advancing both open-chest surgical transplantation and
catheter-based administration approaches, with the goal of bringing transformative regenerative
therapies closer to patients with severe heart failure worldwide.

About Breakthroughs™
Breakthroughs™ is a public-interest PSA series created to help audiences better understand
important advancements in science, medicine, technology, sustainability, infrastructure, and
human progress. Each segment translates complex innovation into clear, credible, visually
compelling public education — highlighting the larger human and societal impact behind
emerging ideas, technologies, and organizations helping shape the future.

Media Contact
For more information visit:
PSAbreakthroughs.org

Lisa Meyers
OMD prm
+1 305-974-1346
lisa.meyers@omdprm.com

This is a special preview of the Heartseed Breakthroughs™ PSA

Media gallery